Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:40 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

ClinicalTrials.gov · NCT04724486 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2020-08-22. Completion: 2022-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

ClinicalTrials.gov · NCT04727684 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Infertility; Intracytoplasmic Sperm Injection; Polycystic Ovary Syndrome
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2020-08-22. Completion: 2022-05-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

ClinicalTrials.gov · NCT04724343 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2019-12-22. Completion: 2022-07-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

ClinicalTrials.gov · NCT04727671 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility; Polycystic Ovary Syndrome
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2019-12-22. Completion: 2021-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Hormonal Stimulation of Spermatogenesis

ClinicalTrials.gov · NCT05483621 · Registry updated: 2023-10-19

Condition / research focus: Azoospermia, Nonobstructive
Sponsor: Egymedicalpedia
Countries with listed sites: Egypt
Registry dates and results: Start: 2021-03-01. Completion: 2022-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beta-hCG (drug)

Where the study takes place — 1 listed sites

Urology department - faculty of medicine, South Valley university
Qina, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

ClinicalTrials.gov · NCT04447872 · Registry updated: 2023-10-16

Condition / research focus: Infertility; Diminished Ovarian Reserve; IVF
Sponsor: Northwell Health
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-15. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Timing of injectable gonadotropins (procedure)

Where the study takes place — 1 listed sites

Northwell Fertility
Manhasset, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Assessing Ketorolac (Toradol) at Oocyte Retrieval

ClinicalTrials.gov · NCT06026553 · Registry updated: 2023-09-07

Condition / research focus: Infertility; Infertility, Female; Oocyte Retrieval; Postoperative Pain; Embryo Transfer
Sponsor: Shady Grove Fertility Reproductive Science Center
Countries with listed sites: United States
Registry dates and results: Start: 2022-08-10. Completion: 2025-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ketorolac (Toradol) (drug)
Placebo (saline) (other)

Where the study takes place — 2 listed sites

Shady Grove Fertility Reproductive Science Center
Rockville, Maryland, United States
Site recruitment: Recruiting
Shady Grove Fertility Reproductive Science Center
Fairfax, Virginia, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

ClinicalTrials.gov · NCT03495609 · Registry updated: 2023-09-07

Condition / research focus: hCG; BRCA1 Mutation; BRCA2 Mutation
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2016-02-17. Completion: 2018-12-18 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Ghent University Hospital
Ghent, East-Flanders, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

ClinicalTrials.gov · NCT03564509 · Registry updated: 2023-08-31

Condition / research focus: Controlled Ovarian Stimulation
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Spain · United Kingdom
Registry dates and results: Start: 2018-05-14. Completion: 2020-01-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FE 999302 (1 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (2 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (4 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (8 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (12 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
Placebo and follitropin delta (other)

Where the study takes place — 20 listed sites

Universitair Ziekenhuis Gent (UZ Gent)
Ghent, Belgium
Site recruitment: Not reported
Universitair Ziekenhuis Brussel
Jette, Belgium
Site recruitment: Not reported
Institut fur Reproduktionsmedizin und Genetik
Karlovy Vary, Czechia
Site recruitment: Not reported
Fertimed
Olomouc, Czechia
Site recruitment: Not reported
GYNEM
Prague, Czechia
Site recruitment: Not reported
IVF CUBE
Prague, Czechia
Site recruitment: Not reported
Aalborg University Hospital
Aalborg, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Dansk Fertilitetsklinik
Frederiksberg, Denmark
Site recruitment: Not reported
Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
Dexeus Woman's Health
Barcelona, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Bilbao
Leioa, Spain
Site recruitment: Not reported
GINEFIV - Clinica Belen Location
Madrid, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Madrid
Madrid, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Sevilla
Seville, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Valencia
Valencia, Spain
Site recruitment: Not reported
Glasgow Royal Infirmary
Glasgow, United Kingdom
Site recruitment: Not reported
Liverpool Women's Hospital
Liverpool, United Kingdom
Site recruitment: Not reported
Guy's and St Thomas' NHS Trust
London, United Kingdom
Site recruitment: Not reported
Kings College (Assisted Conception Unit)
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome

ClinicalTrials.gov · NCT05969834 · Registry updated: 2023-08-01

Condition / research focus: Infertility
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2021-03-31. Completion: 2022-08-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

uHCG (drug) — also listed as: Choriomon
rHCG (drug) — also listed as: Ovitrelle
uHCG and GnRHa (drug) — also listed as: Decapeptyl and Choriomon

Where the study takes place — 1 listed sites

Royal Center
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Dual Trigger for Elective Fertility Preservation

ClinicalTrials.gov · NCT04992468 · Registry updated: 2023-07-25

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-10-05. Completion: 2023-04-25 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovulation triggering with GnRH-a+rhCG (drug)
Ovulation triggering with GnRH-a (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men

ClinicalTrials.gov · NCT04189133 · Registry updated: 2023-07-20

Condition / research focus: Acquired Hypogonadotropic Hypogonadism
Sponsor: Azienda Ospedaliero-Universitaria di Modena
Countries with listed sites: Italy
Registry dates and results: Start: 2022-01-19. Completion: 2026-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lutropin alfa (drug) — also listed as: LH
Human chorionic gonadotropin (drug) — also listed as: hCG

Where the study takes place — 5 listed sites

Fondazione IRCCS Ca ' Grande Ospedale Maggiore Policlinico
Milan, Italy
Site recruitment: Not yet recruiting
Unit of Endocrinology of Modena
Modena, Italy
Site recruitment: Recruiting
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università degli Studi di Napoli "Federico II"
Naples, Italy
Site recruitment: Not yet recruiting
Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza - University of Rome
Rome, Italy
Site recruitment: Not yet recruiting
ivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin
Turin, Italy
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome

ClinicalTrials.gov · NCT05638529 · Registry updated: 2023-07-03

Condition / research focus: Ovarian Hyperstimulation Syndrome; Infertility, Female
Sponsor: Mount Sinai Hospital, Canada
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pregnyl (1,500) IU (drug) — also listed as: Hcg
1.5 mL of normal saline (drug) — also listed as: Normal Saline

Where the study takes place — 1 listed sites

Mount Sinai Hospital, Fertility Clinic
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response

ClinicalTrials.gov · NCT04549649 · Registry updated: 2023-06-15

Condition / research focus: Ovarian Stimulation; Reproductive Techniques, Assisted
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2019-11-01. Completion: 2022-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dual triggering (other)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Extragonadal Effects of hCG on Calcium Homeostasis

ClinicalTrials.gov · NCT03418896 · Registry updated: 2023-06-13

Condition / research focus: Hypogonadism; Calcium Disorder; Renal Disease
Sponsor: Martin Blomberg Jensen
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-01-06. Completion: 2022-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug)

Where the study takes place — 2 listed sites

Department of Growth and Reproduction, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Clinical Observation of Warm Needling Combined With and Electroacupuncture Therapy on Ovulatory Dysfunction

ClinicalTrials.gov · NCT05874518 · Registry updated: 2023-05-25

Condition / research focus: Warm Needling; Electroacupuncture; Ovulation Dysfunction
Sponsor: Liuzhou Maternity and Child Healthcare Hospital
Countries with listed sites: China
Registry dates and results: Start: 2021-12-01. Completion: 2022-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

warm needling combined with electroacupuncture (other)
The treatment with letrozole tablets was started on the fifth day of the menstrual cycle (drug)

Where the study takes place — 1 listed sites

Fanghua Yang
Liuzhou, Guangxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Double Stimulation Followed by a Fresh Embryo Transfer

ClinicalTrials.gov · NCT04446845 · Registry updated: 2023-05-15

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2020-10-30. Completion: 2023-05-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Double Stimulation (Elonva+rFSH) in luteal /follicular phase (drug)
Conventional Stimulation (Elonva+rFSH) in follicular phase (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

ClinicalTrials.gov · NCT04071574 · Registry updated: 2023-05-09

Condition / research focus: Female Infertility; Female Infertility Due to Ovulatory Disorder; Premature Ovarian Failure; Polycystic Ovary Syndrome; Female Infertility of Tubal Origin; Ectopic Pregnancy; Salpingitis; Female Infertility Due to Tubal Block; Female Infertility Due to Tubal Occlusion; Hydrosalpinx; Female Infertility - Cervical/Vaginal; Female Infertility Endocrine; Endometriosis; Fibroids; Congenital Uterine Anomaly; Infections Uterine; Female Infertility of Other Origin
Sponsor: Lebanese University
Countries with listed sites: Lebanon
Registry dates and results: Start: 2018-02-01. Completion: 2023-05-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotropin (hCG) (drug) — also listed as: OVITRELLE / PREGNYL
Gonadotropins (drug) — also listed as: MENOPUR
GNRH-A Triptorelin (drug) — also listed as: DECAPEPTYL
GnRH antagonist (drug) — also listed as: CETROTIDE / ORGULATRON

Where the study takes place — 1 listed sites

Lebanese University, faculty of sciences III
Tripoli, North Lebanon, Lebanon
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

ClinicalTrials.gov · NCT05838105 · Registry updated: 2023-05-01

Condition / research focus: Luteal Phase Support
Sponsor: Shaare Zedek Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2022-10-01. Completion: 2025-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist (drug)
hCG (drug)
Progesterone 100Mg Vag Tab (drug)

Where the study takes place — 1 listed sites

Shaare Zedek medical center
Jerusalem, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Detection of Urinary Human Chorionic Gonadotropin (hCG)

ClinicalTrials.gov · NCT05458778 · Registry updated: 2023-05-01

Condition / research focus: Pregnancy Detection
Sponsor: Quanovate Tech Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2022-06-29. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Daily test with urine by the product (device)

Where the study takes place — 1 listed sites

Quanovate Tech Inc.
San Ramon, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 18:40 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI

ClinicalTrials.gov · NCT04724486 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2020-08-22. Completion: 2022-07-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI

ClinicalTrials.gov · NCT04727684 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Infertility; Intracytoplasmic Sperm Injection; Polycystic Ovary Syndrome
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2020-08-22. Completion: 2022-05-12 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

ClinicalTrials.gov · NCT04724343 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2019-12-22. Completion: 2022-07-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

ClinicalTrials.gov · NCT04727671 · Registry updated: 2023-10-24

Condition / research focus: In Vitro Fertilization; Intracytoplasmic Sperm Injection; Infertility; Polycystic Ovary Syndrome
Sponsor: Damascus University
Countries with listed sites: Syria
Registry dates and results: Start: 2019-12-22. Completion: 2021-12-30 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Triptorelin acetate (drug)
Cetrorelix (drug)
recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin (drug)
Human Chorionic Gonadotropin (hCG) (drug)

Where the study takes place — 1 listed sites

Orient Hospital
Damascus, Syria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Hormonal Stimulation of Spermatogenesis

ClinicalTrials.gov · NCT05483621 · Registry updated: 2023-10-19

Condition / research focus: Azoospermia, Nonobstructive
Sponsor: Egymedicalpedia
Countries with listed sites: Egypt
Registry dates and results: Start: 2021-03-01. Completion: 2022-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Beta-hCG (drug)

Where the study takes place — 1 listed sites

Urology department - faculty of medicine, South Valley university
Qina, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

ClinicalTrials.gov · NCT04447872 · Registry updated: 2023-10-16

Condition / research focus: Infertility; Diminished Ovarian Reserve; IVF
Sponsor: Northwell Health
Countries with listed sites: United States
Registry dates and results: Start: 2020-09-15. Completion: 2025-06 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Timing of injectable gonadotropins (procedure)

Where the study takes place — 1 listed sites

Northwell Fertility
Manhasset, New York, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

Assessing Ketorolac (Toradol) at Oocyte Retrieval

ClinicalTrials.gov · NCT06026553 · Registry updated: 2023-09-07

Condition / research focus: Infertility; Infertility, Female; Oocyte Retrieval; Postoperative Pain; Embryo Transfer
Sponsor: Shady Grove Fertility Reproductive Science Center
Countries with listed sites: United States
Registry dates and results: Start: 2022-08-10. Completion: 2025-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ketorolac (Toradol) (drug)
Placebo (saline) (other)

Where the study takes place — 2 listed sites

Shady Grove Fertility Reproductive Science Center
Rockville, Maryland, United States
Site recruitment: Recruiting
Shady Grove Fertility Reproductive Science Center
Fairfax, Virginia, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

ClinicalTrials.gov · NCT03495609 · Registry updated: 2023-09-07

Condition / research focus: hCG; BRCA1 Mutation; BRCA2 Mutation
Sponsor: University Hospital, Ghent
Countries with listed sites: Belgium
Registry dates and results: Start: 2016-02-17. Completion: 2018-12-18 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovitrelle (drug)

Where the study takes place — 1 listed sites

Ghent University Hospital
Ghent, East-Flanders, Belgium
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

ClinicalTrials.gov · NCT03564509 · Registry updated: 2023-08-31

Condition / research focus: Controlled Ovarian Stimulation
Sponsor: Ferring Pharmaceuticals
Countries with listed sites: Belgium · Czechia · Denmark · Spain · United Kingdom
Registry dates and results: Start: 2018-05-14. Completion: 2020-01-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

FE 999302 (1 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (2 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (4 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (8 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
FE 999302 (12 μg) and follitropin delta (drug) — also listed as: Choriogonadotropin beta
Placebo and follitropin delta (other)

Where the study takes place — 20 listed sites

Universitair Ziekenhuis Gent (UZ Gent)
Ghent, Belgium
Site recruitment: Not reported
Universitair Ziekenhuis Brussel
Jette, Belgium
Site recruitment: Not reported
Institut fur Reproduktionsmedizin und Genetik
Karlovy Vary, Czechia
Site recruitment: Not reported
Fertimed
Olomouc, Czechia
Site recruitment: Not reported
GYNEM
Prague, Czechia
Site recruitment: Not reported
IVF CUBE
Prague, Czechia
Site recruitment: Not reported
Aalborg University Hospital
Aalborg, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Dansk Fertilitetsklinik
Frederiksberg, Denmark
Site recruitment: Not reported
Hvidovre Hospital
Hvidovre, Denmark
Site recruitment: Not reported
Dexeus Woman's Health
Barcelona, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Bilbao
Leioa, Spain
Site recruitment: Not reported
GINEFIV - Clinica Belen Location
Madrid, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Madrid
Madrid, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Sevilla
Seville, Spain
Site recruitment: Not reported
Instituto Valenciano de Infertilidad (IVI) - Valencia
Valencia, Spain
Site recruitment: Not reported
Glasgow Royal Infirmary
Glasgow, United Kingdom
Site recruitment: Not reported
Liverpool Women's Hospital
Liverpool, United Kingdom
Site recruitment: Not reported
Guy's and St Thomas' NHS Trust
London, United Kingdom
Site recruitment: Not reported
Kings College (Assisted Conception Unit)
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

HCG Levels After Ovulation Triggering as Predictors of ICSI Outcome

ClinicalTrials.gov · NCT05969834 · Registry updated: 2023-08-01

Condition / research focus: Infertility
Sponsor: Mansoura University
Countries with listed sites: Egypt
Registry dates and results: Start: 2021-03-31. Completion: 2022-08-07 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

uHCG (drug) — also listed as: Choriomon
rHCG (drug) — also listed as: Ovitrelle
uHCG and GnRHa (drug) — also listed as: Decapeptyl and Choriomon

Where the study takes place — 1 listed sites

Royal Center
Al Mansurah, Dakahlia Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Dual Trigger for Elective Fertility Preservation

ClinicalTrials.gov · NCT04992468 · Registry updated: 2023-07-25

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2021-10-05. Completion: 2023-04-25 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ovulation triggering with GnRH-a+rhCG (drug)
Ovulation triggering with GnRH-a (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men

ClinicalTrials.gov · NCT04189133 · Registry updated: 2023-07-20

Condition / research focus: Acquired Hypogonadotropic Hypogonadism
Sponsor: Azienda Ospedaliero-Universitaria di Modena
Countries with listed sites: Italy
Registry dates and results: Start: 2022-01-19. Completion: 2026-01-18 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Lutropin alfa (drug) — also listed as: LH
Human chorionic gonadotropin (drug) — also listed as: hCG

Where the study takes place — 5 listed sites

Fondazione IRCCS Ca ' Grande Ospedale Maggiore Policlinico
Milan, Italy
Site recruitment: Not yet recruiting
Unit of Endocrinology of Modena
Modena, Italy
Site recruitment: Recruiting
Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università degli Studi di Napoli "Federico II"
Naples, Italy
Site recruitment: Not yet recruiting
Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza - University of Rome
Rome, Italy
Site recruitment: Not yet recruiting
ivision of Endocrinology, Diabetes and Metabolism, Department of Medical Science, University of Turin
Turin, Italy
Site recruitment: Not yet recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome

ClinicalTrials.gov · NCT05638529 · Registry updated: 2023-07-03

Condition / research focus: Ovarian Hyperstimulation Syndrome; Infertility, Female
Sponsor: Mount Sinai Hospital, Canada
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Pregnyl (1,500) IU (drug) — also listed as: Hcg
1.5 mL of normal saline (drug) — also listed as: Normal Saline

Where the study takes place — 1 listed sites

Mount Sinai Hospital, Fertility Clinic
Toronto, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response

ClinicalTrials.gov · NCT04549649 · Registry updated: 2023-06-15

Condition / research focus: Ovarian Stimulation; Reproductive Techniques, Assisted
Sponsor: Royan Institute
Countries with listed sites: Iran
Registry dates and results: Start: 2019-11-01. Completion: 2022-11-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dual triggering (other)

Where the study takes place — 1 listed sites

Royan Institute
Tehran, Iran
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Extragonadal Effects of hCG on Calcium Homeostasis

ClinicalTrials.gov · NCT03418896 · Registry updated: 2023-06-13

Condition / research focus: Hypogonadism; Calcium Disorder; Renal Disease
Sponsor: Martin Blomberg Jensen
Countries with listed sites: Denmark
Registry dates and results: Start: 2018-01-06. Completion: 2022-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

human chorionic gonadotropin (drug)

Where the study takes place — 2 listed sites

Department of Growth and Reproduction, Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported
Rigshospitalet
Copenhagen, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Clinical Observation of Warm Needling Combined With and Electroacupuncture Therapy on Ovulatory Dysfunction

ClinicalTrials.gov · NCT05874518 · Registry updated: 2023-05-25

Condition / research focus: Warm Needling; Electroacupuncture; Ovulation Dysfunction
Sponsor: Liuzhou Maternity and Child Healthcare Hospital
Countries with listed sites: China
Registry dates and results: Start: 2021-12-01. Completion: 2022-04-30 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

warm needling combined with electroacupuncture (other)
The treatment with letrozole tablets was started on the fifth day of the menstrual cycle (drug)

Where the study takes place — 1 listed sites

Fanghua Yang
Liuzhou, Guangxi, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Double Stimulation Followed by a Fresh Embryo Transfer

ClinicalTrials.gov · NCT04446845 · Registry updated: 2023-05-15

Condition / research focus: Infertility
Sponsor: Fundación Santiago Dexeus Font
Countries with listed sites: Spain
Registry dates and results: Start: 2020-10-30. Completion: 2023-05-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Double Stimulation (Elonva+rFSH) in luteal /follicular phase (drug)
Conventional Stimulation (Elonva+rFSH) in follicular phase (drug)

Where the study takes place — 1 listed sites

Hospital Universitario Quiron Dexeus
Barcelona, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1 / Phase 2CompletedINTERVENTIONAL

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

ClinicalTrials.gov · NCT04071574 · Registry updated: 2023-05-09

Condition / research focus: Female Infertility; Female Infertility Due to Ovulatory Disorder; Premature Ovarian Failure; Polycystic Ovary Syndrome; Female Infertility of Tubal Origin; Ectopic Pregnancy; Salpingitis; Female Infertility Due to Tubal Block; Female Infertility Due to Tubal Occlusion; Hydrosalpinx; Female Infertility - Cervical/Vaginal; Female Infertility Endocrine; Endometriosis; Fibroids; Congenital Uterine Anomaly; Infections Uterine; Female Infertility of Other Origin
Sponsor: Lebanese University
Countries with listed sites: Lebanon
Registry dates and results: Start: 2018-02-01. Completion: 2023-05-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human Chorionic Gonadotropin (hCG) (drug) — also listed as: OVITRELLE / PREGNYL
Gonadotropins (drug) — also listed as: MENOPUR
GNRH-A Triptorelin (drug) — also listed as: DECAPEPTYL
GnRH antagonist (drug) — also listed as: CETROTIDE / ORGULATRON

Where the study takes place — 1 listed sites

Lebanese University, faculty of sciences III
Tripoli, North Lebanon, Lebanon
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Two Different Types of Luteal Phase Support in Natural Cycle Frozen Embryo Transfer and Its Effect on Pregnancy Rates

ClinicalTrials.gov · NCT05838105 · Registry updated: 2023-05-01

Condition / research focus: Luteal Phase Support
Sponsor: Shaare Zedek Medical Center
Countries with listed sites: Israel
Registry dates and results: Start: 2022-10-01. Completion: 2025-01-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH agonist (drug)
hCG (drug)
Progesterone 100Mg Vag Tab (drug)

Where the study takes place — 1 listed sites

Shaare Zedek medical center
Jerusalem, Israel
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Detection of Urinary Human Chorionic Gonadotropin (hCG)

ClinicalTrials.gov · NCT05458778 · Registry updated: 2023-05-01

Condition / research focus: Pregnancy Detection
Sponsor: Quanovate Tech Inc.
Countries with listed sites: United States
Registry dates and results: Start: 2022-06-29. Completion: 2023-10-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Daily test with urine by the product (device)

Where the study takes place — 1 listed sites

Quanovate Tech Inc.
San Ramon, California, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →